5 Best One Dollar Stocks To Buy Now

3. Harpoon Therapeutics, Inc. (NASDAQ:HARP)

Number Of Hedge Fund Holders: 12

Share Price as of August 1: $1.93

Harpoon Therapeutics, Inc. (NASDAQ:HARP) is a clinical-stage immunotherapy company engaged in the development of novel T cell engagers (TriTACs) for the treatment of cancer. The company has a discovery collaboration and license agreement with AbbVie Inc. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors.

Canaccord analyst William Maughan assumed coverage of Harpoon Therapeutics, Inc. (NASDAQ:HARP) with a Buy rating and $16 price target. Bispecific T-cell engagers, like the ones Harpoon is developing, are “among the hottest therapeutic strategies in development for oncology,” said Maughan, who adds that Harpoon Therapeutics has been “a pioneer in the field.” He thinks the recent memory of setbacks and a financing overhang are keeping investors on the sidelines. However, he argues that the Harpoon platform “remains solid.”

Among the hedge funds tracked by Insider Monkey, Harpoon Therapeutics, Inc. (NASDAQ:HARP) was part of 12 public stock portfolios at the end of Q1 2022, compared to 14 funds in the earlier quarter. Samuel Isaly’s OrbiMed Advisors is the leading stakeholder of the company, with 3.03 million shares worth $15.1 million.